ZCG-Backed Techniks Tool Group to Acquire Eppinger Group to Create Global, Leading Tooling Solutions Provider
27.3.2023 12:00:00 CEST | Business Wire | Press Release
Techniks Tool Group (“TTG)”, one of the largest manufacturers and suppliers of branded highly engineered, consumable, high-cost-of-failure aftermarket and OEM tooling products in North America, today announced that it has entered into a definitive agreement to acquire Eppinger Group (“Eppinger”), a Denkendorf / Baden-Württemberg, Germany-based leading designer and manufacturer of sophisticated, high precision static and live tools, complete CNC (Computerized Numerical Control) tooling systems, rotary tables for CNC machines, and gears and gearboxes for robotics applications. TTG is a portfolio company of Z Capital Partners, L.L.C., the private equity fund management arm of Z Capital Group, L.L.C. ("ZCG"), a leading privately held merchant bank. The transaction is expected to close later this week.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230326005063/en/
Z Capital Group (Graphic: Business Wire)
Founded in 1925, Eppinger is one of the leading mechanical engineering companies in the field of development and production of tool holders, specifically for CNC turning & milling centers and precision gears. Eppinger has three manufacturing and distribution facilities located in Germany, India, and the U.S. and holds extensive direct relationships with machine shops, machine OEMs and robot manufacturers in Europe and Asia.
The combined business will be named Eppinger Technologies and will expand its broad product offering of highly engineered solutions to cover both milling and lathe CNC machines. Eppinger leadership, including CEO Uwe Eppinger, will remain with the combined business. Mr. Eppinger will also remain an investor in the combined company.
"This transaction will enhance our global positioning and provide us with a broader platform, expanded manufacturing and distribution channels, and a wider customer set from which to grow," said Dean Glover, CEO of TTG. "The combined entity will be renamed Eppinger Technologies, and we will continue to build upon our industry-leading channel presence and diversified suite of products."
“We are pleased to add Eppinger, a company with a rich German engineering history in providing the highest quality products to its customers, to our portfolio. Eppinger is a highly complementary business to Techniks Tool Group and together, they represent an extremely compelling partner in the attractive tooling market,” said James Zenni, Founder, President and Chief Executive Officer of ZCG. “We look forward to building on this strategic combination to continue to capture market share and drive substantial global growth.”
“For nearly 100 years, Eppinger has focused on providing the finest high-quality solutions for our customers,” said Mr. Eppinger. “We were attracted to the ZCG team and Techniks Tool Group because they share our focus on innovation, superior quality, technical support and customer service, and we are excited to partner together to address the technical needs of an expanded customer base across the market spectrum.”
About Eppinger
The Eppinger Group is a company based in Denkendorf / Baden-Württemberg. The company has been specializing in precision tools for lathes for almost 100 years and is a leader in the design and manufacture of tool holders for CNC Turning & Milling Centres. Eppinger currently has more than 53 patents underpinning a product range that includes fixed and driven tool holders and complete tool systems.
Recent Eppinger Innovations include rotary tables and industry leading precision gear units that are used in all areas of mechanical engineering.
The product range includes angular and coaxial gear units as well as geared motors for a wide variety of applications in automation, robotics and mechanical engineering. The high-quality products occupy a leading position on the international market. Eppinger offers individual and end-to-end solutions from a single source: from development and design to production. For more information, please visit https://eppinger.de/en/.
About Techniks Tool Group
Techniks Tool Group is the North American industry leader in high quality branded toolholding and workholding solutions for demanding and high precision CNC applications. TTG has an unparalleled network spanning the manufacturing and tooling industries with a focus on strategic supplier relationships, leading channel access, extensive engineering capabilities and unmatched customer support. For more information, please visit www.technikstoolgroup.com.
About ZCG
ZCG is a leading, privately held merchant bank comprised of private markets asset management, business consulting services, technology development and solutions.
For almost 30 years, ZCG Principals have invested tens of billions in capital and have industry leading track records in private equity and credit.
ZCG has approximately $6.5B of AUM in asset management and its investors are some of the largest and most sophisticated global institutional investors including pension funds, endowments, foundations, sovereign wealth funds, central banks, and insurance companies.
ZCG has a global team comprised of over 375 professionals. For more information, please visit www.zcg.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230326005063/en/
Contact information
Joele Frank, Wilkinson Brimmer Katcher
Tim Ragones / Kate Thompson / Erik Carlson
212-355-4449
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press Release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press Release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom